A systems biology approach was developed to study in detail the effect of HER2 inhibitors (trastuzumab, pcrtuzumab) on the response of the ERK/PI3K/PTEN/AKT
Antibodies specific for cell surface receptors overexpressed on a number of cancers have been utilized for development of targeted immunotherapeutics.Identi